Evidence map›Paper›PMID 27214073›Full record

Trial reportBone marrow transplantation2016

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).

P Montesinos, M Cabrero, D Valcárcel, M Rovira, J A García-Marco, J Loscertales, C Moreno, R Duarte, M J Terol, N Villamor and 4 more

Registry-linked trialAbstract readClinical TrialLetter
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01455051 (Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01455051 phase2completednot on this map

Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC

TypeinterventionalSponsorGrupo Espanol de trasplantes hematopoyeticos y terapia celularRan2011 to 2017Enrolled25ConditionsChronic Lymphocytic LeukemiaArmsOfatumumab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

P MontesinosDepartment of Haematology, Hospital La Fe, Valencia, Spain.
M CabreroDepartment of Haematology, Hospital Clínico, Salamanca, Spain.
D ValcárcelDepartment of Haematology, Hospital Vall d'Hebron, Barcelona, Spain.
M RoviraDepartment of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.
J A García-MarcoDepartment of Haematology, Hospital Puerta de Hierro, Majadahonda, Spain.
J LoscertalesDepartment of Haematology, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain.
C MorenoDepartment of Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
R DuarteDepartment of Haematology, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain.
M J TerolDepartment of Haematology, Hospital Clínic, Valencia, Spain.
N VillamorHaematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain.
P AbrisquetaDepartment of Haematology, Hospital Vall d'Hebron, Barcelona, Spain.
D CaballeroDepartment of Haematology, Hospital Clínico, Salamanca, Spain.
J SanzDepartment of Haematology, Hospital La Fe, Valencia, Spain.
J DelgadoDepartment of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntigens, CD20FemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPilot ProjectsRecurrenceRisk FactorsSecondary PreventionSurvival AnalysisTransplantation ConditioningAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntigens, CD20ofatumumab

Identifiers

PMID27214073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.